HTA trials will no longer infringe UK patent law
This article was originally published in Scrip
Executive Summary
A legal obstacle to the conduct of clinical trials in the UK should be removed by October 1, if recommendations from the UK government are followed. The UK’s narrow interpretation of the research exceptions to the 1977 UK Patents Act had meant that companies conducting comparative clinical research in the UK were open to prosecution for patent infringement. The government has now recommended a broader interpretation of the exceptions that aligns the UK with other major European nations and, according to industry associations, promises to make the UK a more attractive venue for comparative trials.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.